Bio-economy news

Subscribe to Bio-economy news feed Bio-economy news
Business Wire - The global leader in news distribution
Updated: 56 min 15 sec ago

Aurinia to Participate in Upcoming Investor Conferences

4 hours 56 min ago
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc., (NASDAQ:AUPH)(TSX:AUP) today announced its Chairman and CEO, Richard Glickman, will present a company overview at two upcoming investor conferences. The presentations will be webcast live and can be accessed via the investor section of the Aurinia website, A replay of each presentation will also be archived on the site following the event. Monday, October 1, 2018, Aurinia will present at the Cantor

IMBiotechnologies Ltd Announces Presentation at the 2018 Cardiovascular and Interventional Radiological Society of Europe Annual Meeting (Lisbon, Portugal)

8 hours 56 min ago
EDMONTON, Alberta--(BUSINESS WIRE)--IMBiotechnologies Ltd. today announced that an oral presentation regarding the use of its lead product, Occlusin® 500 Embolization Microspheres (Occlusin 500), in benign prostatic hypertrophy (BPH) patients will be presented at the 2018 Cardiovascular and Interventional Radiological Society of Europe (CIRSE) annual meeting. Dr. Richard Owen, lead investigator of the clinical study conducted at the University of Alberta Hospital, will be presenting qualitative

Sunovion Announces Health Canada Approval of Aptiom® (eslicarbazepine acetate) as Adjunctive Therapy for the Treatment of Partial-Onset Seizures in Adolescents and Children Above Six Years of Age

12 hours 56 min ago
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion announces Health Canada approval of Aptiom® as adjunctive therapy for the treatment of partial-onset seizures in adolescents and children

Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX® (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma

13 hours 56 min ago
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced that its partner Ipsen Biopharmaceuticals Canada Inc. received approval from Health Canada of CABOMETYX® (cabozantinib) tablets for the treatment of adults with advanced renal cell carcinoma (RCC) who have received prior vascular endothelial growth factor (VEGF) targeted therapy. Health Canada granted CABOMETYX priority review status, which provided an accelerated review of Ipsen’s new drug submission. “The approval

Zymeworks Names Anthony Polverino, Ph.D., Executive Vice President of Early Development and Chief Scientific Officer

14 hours 56 min ago
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced it has named Anthony (Tony) Polverino, Ph.D., Executive Vice President of Early Development and Chief Scientific Officer. In his new role, Dr. Polverino will be instrumental in setting and driving Zymeworks’ R&D strategy. He will also manage the advancement of product candidates from discovery research through tran

Life Sciences Ontario Hosts Minister Navdeep Bains and Mayor Bonnie Crombie in Roundtable on Opportunities and Challenges Facing Canada’s Life Sciences Sector

Tue, 18/09/2018 - 11:00
TORONTO--(BUSINESS WIRE)--On September 10th, 2018, Life Sciences Ontario hosted a roundtable discussion with the Minister of Innovation, Science and Economic Development, Navdeep Bains, and Mississauga Mayor Bonnie Crombie, along with key industry partners from the life sciences sector. The session, held at JLABS in MaRS, was led by Dr. Jason Field, President and CEO of Life Sciences Ontario; it was attended on behalf of industry by Chris Halyk, President of Janssen; Susan Marlin, President and

Aspect Biosystems Announces Liver Tissue Collaboration with JSR

Tue, 18/09/2018 - 09:00
VANCOUVER, British Columbia--(BUSINESS WIRE)--#3Dprinting--Biotech company Aspect Biosystems announces collaboration with multinational JSR Corporation to develop human liver tissue.

Klick Health Uses Body Slams and Dropkicks to Tackle Carcinoid Syndrome Awareness and Win 2018 PM360 Trailblazer Award

Mon, 17/09/2018 - 15:00
NEW YORK & TORONTO--(BUSINESS WIRE)--Klick Health’s The Wrestler, an unbranded pharma ad campaign with comedic dropkicks and body slams, has received a 2018 PM360 Trailblazer Award.

Industry leader Geoff Mackay to Chair board of Satellos Bioscience

Mon, 17/09/2018 - 09:00
TORONTO--(BUSINESS WIRE)--Satellos Bioscience announces appointment of stem cell industry leader Geoff Mackay as Board Chair

Acerus Announces Publication of Manuscript Reporting Early Data from Partner-Sponsored Natesto® Spermatogenesis Study

Mon, 17/09/2018 - 08:00
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX: ASP) (“Acerus” or the “Company”) today announced the publication of a clinical trial update in the journal European Urology Focus on the effects of Natesto® on reproductive hormones and semen parameters. This study is being conducted at the University of Miami's Department of Urology, and Dr. Ranjith Ramasamy, MD, the Director of Reproductive Urology, is the study's principal investigator. The Company’s partner, Aytu BioScience

Covalon to Showcase IV Clear at AVA Scientific Meeting 2018

Fri, 14/09/2018 - 15:00
MISSISSAUGA, Ontario--(BUSINESS WIRE)--#AVA--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV.V; OTCQX: CVALF), an advanced medical technologies company, today announces that it will be showcasing IV Clear at the 2018 Scientific Meeting for the Association for Vascular Access (“AVA” or the “Meeting”). Covalon’s IV Clear™ is indicated to cover and protect vascular access devices used in a wide variety of both acute and alternate care settings. Its patented combination of chlorhexidine

World Sepsis Day - Sepset Biosciences Inc. is Raising Awareness about One of the Most Prevalent and Deadly, Yet Misdiagnosed, Medical Conditions

Thu, 13/09/2018 - 12:04
VANCOUVER, British Columbia--(BUSINESS WIRE)--#biotech--Noting World Sepsis Day, Sepset Biosciences Inc., a spin-out company of The Centre for Drug Research and Development (CDRD) in collaboration with Dr. Robert Hancock at The University of British Columbia, is raising awareness about sepsis: a serious medical condition that is the body’s overwhelming and life-threatening response to infection that can lead to tissue damage, organ failure, and death. It more common than heart attack and claims more live

CPDC and McMaster Nuclear Reactor Sign Research Agreement for Production of High Value Medical Isotopes

Thu, 13/09/2018 - 07:00
HAMILTON, Ontario--(BUSINESS WIRE)--#nuclearmedicine--The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, and the McMaster Nuclear Reactor facility (MNR), a leading research reactor program that provides a source of medical radioisotopes, announced today that they have signed an agreement to explore the development of processes to produce rare and high-value medical radioisotopes utilizing the nuclear reactor

Global Spine Market to Reach $18 Billion by 2023 According to New Analysis by iData Research

Thu, 13/09/2018 - 07:00
VANCOUVER, British Columbia--(BUSINESS WIRE)--#backpain--iData Research releases new research analyzing the global spine market. This market is valued at over $14 billion and will grow to $18 billion by 2023

MRM Proteomics Inc and Exactis Innovation Partner to Establish Unique Clinical Proteomics Tools for Precision Medicine

Wed, 12/09/2018 - 15:50
MONTREAL--(BUSINESS WIRE)--#CancerResearch--MRM Proteomics Inc. is partnering with Exactis Innovation to develop and validate a clinical proteomic test that will provide clinicians and scientists with the ability to identify immune signatures and tumour mutation profiles to better match patients with the most effective treatments. The novel diagnostic test will be the first immuno-MALDI test to measure the activity of multiple cancer-associated proteins in patients’ tumours. This approach has the potential to t

Sunovion Announces Health Canada Acceptance of New Drug Submission for Apomorphine Sublingual Film (APL-130277)

Wed, 12/09/2018 - 08:45
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion announced today that Health Canada has accepted the NDS for apomorphine sublingual film (APL-130277) for people with Parkinson's disease.

Systems Oncology Announces the ExpansiveAI Project to Advance Artificial Intelligence Capable of Imagination

Wed, 12/09/2018 - 06:42
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Systems Oncology Announces the ExpansiveAI Project to Advance Artificial Intelligence Capable of Imagination

Celltrion Announces FDA Oncologic Drugs Advisory Committee Meeting Schedule for Proposed Biosimilar to Rituxan® (Rituximab)

Wed, 12/09/2018 - 03:41
INCHEON, South Korea--(BUSINESS WIRE)--#CTP10--Celltrion announced that the U.S. FDA scheduled the BLA for CT-P10, a proposed monoclonal Antibody biosimilar to Rituxan®, for discussion by the ODAC.

CCAB And Triumvira Immunologics Announce Triumvira’s License Agreement with University of Toronto for the Discovery of Antibody Drug Development Candidates

Mon, 10/09/2018 - 09:21
AUSTIN, Texas & HAMILTON, Ontario & TORONTO--(BUSINESS WIRE)--Triumvira enters into exclusive licensing agreement with University of Toronto for antibodies discovered there on specified cancer targets.

Cyclenium Pharma and Haplogen Bioscience Announce Granting of EUREKA Label and Funding to Develop Novel Therapies in Severe Viral Diseases

Mon, 10/09/2018 - 07:21
MONTREAL & VIENNA--(BUSINESS WIRE)--#biobucks--Cyclenium Pharma and Haplogen receive prestigious Eureka label and funding to discover therapeutics against flaviviruses including dengue and Zika.